|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
23
|
|
pubmed:dateCreated |
2000-1-13
|
|
pubmed:abstractText |
Blockers of the human Kv1.3 potassium channel were designed using Biosym/MSI's ligand design program LUDI. Parallel combinatorial synthesis of the resultant substituted phenyl-stilbenes on solid phase, followed by 125I Charybdotoxin (125I ChTx) screening, yielded 12 Kv1.3 channel blockers with modest activity.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
0960-894X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
6
|
|
pubmed:volume |
9
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
3267-72
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
|
|
pubmed:year |
1999
|
|
pubmed:articleTitle |
Blockers of human T cell Kv1.3 potassium channels using de novo ligand design and solid-phase parallel combinatorial chemistry.
|
|
pubmed:affiliation |
Department of Chemistry, University of California, Irvine 92697, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
